Ono Pharmaceutical
Ono Pharmaceutical Co., Ltd., commonly referred to as Ono Pharma, is a leading biopharmaceutical company headquartered in Osaka, Japan. Founded in 1717, Ono has established itself as a key player in the pharmaceutical industry, focusing on innovative drug discovery and development, particularly in oncology, immunology, and pain management. With a strong presence in Japan and expanding operations in North America and Europe, Ono is renowned for its flagship product, Opdivo (nivolumab), a groundbreaking immunotherapy that has transformed cancer treatment. The company’s commitment to research and development has led to significant milestones, including strategic partnerships and a robust pipeline of novel therapeutics. Ono Pharmaceutical's dedication to advancing healthcare solutions has positioned it as a prominent force in the global market, recognised for its contributions to improving patient outcomes and enhancing quality of life.
DitchCarbon Score
How does Ono Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Instruments industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ono Pharmaceutical's score of 52 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ono Pharmaceutical's reported carbon emissions
In 2023, Ono Pharmaceutical reported total greenhouse gas (GHG) emissions of approximately 16.7 million tonnes CO2e, comprising 6.7 million tonnes from Scope 1, 14.4 million tonnes from Scope 2, and 6.7 million tonnes from Scope 3 emissions. The company has set ambitious targets to significantly reduce its carbon footprint, committing to a 55% reduction in absolute Scope 1 and 2 emissions by FY2030 and achieving net-zero emissions by FY2050, using FY2017 as the baseline year. Additionally, Ono aims to reduce its absolute Scope 3 emissions by 30% by FY2030 and 60% by FY2050. These targets align with the Science Based Targets initiative (SBTi) and reflect Ono's commitment to addressing climate change and promoting sustainability within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | 00,000,000 | 000,000,000 | 000,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ono Pharmaceutical is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
